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Human Primary Immunodeficiency syndromes 
Primary immunodeficiency diseases (PIDs) represent a group of most 
heterogeneous syndromes characterized by development or functional defect of the 
Immune system.  More than 100 inherited conditions described immunodeficiencies 
exist (Chapel, H. 2003; Fischer, A. 2001; Buckley R. H. 2000).   Clinical 
presentation is highly variable, ranging from various patterns of microbial 
susceptibility to allergy, lymphoproliferation or autoimmune manifestation the most 
of these syndromes are monogenic and lead to defects in any aspect of the immune 
response.  Although several form of them occur in the first time of life there are 
many other disorders in which the clinical manifestation develop during adulthood.  
A great contribution to understanding the genetic basis of PIDs came up from recent 
report on using tools developed to study the human genome, approximately 100 
genes associated to PIDs have been identified so far (Chapel, H. 2003; Fischer, A. 
2001; Buckley R. H. 2000).  Along with classical form in with there are clear sign of 
immune defect there are often several form in which the clinical features of immune 
defect are not completely clear so many cases are misdiagnosed.  In many cases, 
inherited diseases have led to the identification of new gene that are crucial in 
immune cell development or effector function, thus contributing to homeostatic 
mechanisms that keep the immune system in check to prevent overt autoimmune 
disease.  In particular, in the last years the attention has been focused on the several 
form of ID in which an alteration of homeostatic mechanism is involved.  The 
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process which is involved in the control of immunological homeostasis named  
apoptosis or programmed cell death that exert its important role trough specialized 
cells.   These cells play their role of maintenance of the immune homeostasis through 
two principal mechanism: the secretory and non secretory pathway that will be 
illustrated below.   
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Molecular basis of killing by CTLs and NK cells 
CTLs and NK cells are critical for the host defense against pathogenic 
microorganisms and malignant cells (Russell J.H. et al 2002).  When CTLs 
recognize target cells, the T-cell receptor (TCR) on the cell surface of CTLs engages 
with major histocompatibility complex (MHC) class I. Signals from the TCR 
activate both the non secretory pathway, known as the Fas mediated pathway, and 
the secretory pathway, that involves the perforin (PRF1)/granzyme mediated 
signaling (Kagi D. et al 1996).  Genetic defects of both pathways have been 
described.  These defect lead to completely distinct clinical and immunological 
phenotypes.  There are 18 identified monogenic diseases that disturb the immune 
system homeostasis of either innate or adaptative immunity (Table 1).  Both 
pathways play a key role in the capacity of immune system to maintain a state of 
dynamic equilibrium despite recurrent exposure to a diverse array of organisms and 
constant exposure to self-antigens.  These immune cell death pathways allow the 
immune response to be self-limited and decline with time after antigenic stimulation.  
Alterations of both these mechanisms of control of the immune response may be 
responsible for an alteration in the homeostasis thus leading to inappropriate 
response to viral infections and massive lymphohistiocytic activation syndromes or 
hyperimmune syndromes, respectively.   
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Table 1 
Disease Inheritance Gene/Product Mechanism Affected cells 
Haemophagocytic 
Syndrome 
    
Familial 
Lymphohistiocytosis 
AR PRF1 
Munch-13 
Snx11 
Defective 
lymphocytes 
cytotoxicity 
T +NK 
lymphocytes 
Griscelli Disease AR Rab27   
Chediack-Higashi 
disese 
AR CHS/LYST   
X-linked proliferative 
disese 
XL SH2D1A/SAP   
Autoimmune 
Lymphoproliferative 
disease 
AD  
(AR) 
TNFRSF6/Fas 
Casp10/Caspase 
10 
Defective 
lymphocytes 
apoptosis 
T+B 
lymphocytes 
APECED AR AIRE Faulty T cell 
central 
tolerance 
T 
lymphocytes 
Ipex XL FOXP3 Defective 
regulatory 
cells 
T 
lymphocytes 
Immunodeficiency 
with lymphoid 
infiltration 
AR IL2RA Defective 
regulatory T 
cells 
activity ? 
T 
lymphocytes 
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Non secretory pathway 
 
In particular, the non secretory pathway functionally specialized membrane 
receptors.  These receptors, called death receptors, belong to TNF-receptor (TNF-
R)/NGF-receptor (NGF-R) superfamily which contain cysteine-rich domains (CRDs) 
in the extracytoplasmic region.  The extracellular portion of these proteins is 
important for ligand binding.  Furthermore, these proteins are characterized by the 
presence of a functional domain named “death domain” (DD) in the cytoplasmic 
region, that binds the cytoplamic signaling proteins essential to induce apoptosis 
(Kischkel F.C. et al 1995).  Fas, also known as CD95 or Apo-1 or TNFRSF6 belongs 
to this family of proteins and is the most efficient inducer of apoptosis in the 
lymphocytes.  The molecule consists of 3 extracellular CRDs and of 80 amino acid 
residues in the intracellular DD.  Fas ligand (FasL), molecule that belong to the TNF 
superfamily of the type II transmembrane proteins activate this receptor.  The 
intracellular and extracellular domains of FasL are located in the N- and C-terminal 
regions, respectively.  The receptor-binding domain is located at the very end of the 
C-terminus, and deletion of at least three amino acids from this region is sufficient to 
interfere with interactions with its receptor, Fas (Kavurma M.M. et al 2003).  After 
ligand binding, three molecules of Fas assemble into complexes.  Fas signaling 
occurs through the interaction of Fas with the Fas Associated Death Domain 
(FADD), a cellular adaptor and, subsequently, with procaspases 8 and/or 10 in a 
death inducing signaling complex (DISC) (Rieux-Laucat F. et al 2003). (Figure 1)   
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Secretory pathway 
 
PRF1 is present in granules of CTLs and NK cells.  Cytotoxic granules gather 
at site of contact between the CTL and the target cell, known as the immunological 
synapse.  The granule membrane fuses with the cell membrane and releases the 
contents of the granules in a process referred to as exocytosis.  This results in rapid 
death of the target cell.  This cell death mechanism also involves the secretion and a 
series of serine proteases called granzymes.  Secreted PRF1 inserts into the lipid 
bilayer thorough specific receptor, while the granzymes are potent activator of the 
caspases.  In fact they induce the cleavage of the caspases, including the caspase 3 
(Darmon A. J. et al 1995).  The most recent model shows that the adhesion of the 
cytotoxic T lymphocytes to the target cell, via the interaction between the TCR and 
the antigen-MHC complex, triggers a Ca2+dependent degranulation process in the 
effector cells.  The degranulation process, causes the release of PRF1, which 
recognizes the mannose-6-phosphate receptor (MPR), thus leading to a 
macromolecular complex, along granzymes.  Eventually, the macromolecular 
complex results in the target cell lysis.  (Figure 2) 
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Figure 2. Evolving models of CTL/NK-secretory pathway. A The initial model, 
which was developed in the early 1980s when perforin was first purified, 
emphasized the role of perforin as lytic molecule. The target cell died because of loss 
of plasma membrane homeostasis, with excessive uptake of water and loss of 
intracellular contents.  B With the realization that granzymes are involved in the 
inducing cell death cooperatively with perforin,and that many cells die by apoptosis, 
the lytic model was adapted to accommodate the passive diffusion of granzymes into 
the target cell cytosol, where they could access key substrate (caspase), leading to 
death.  C The next main findings to be accommodated in the model during the mid to 
late 1990s were that: granzymes enter target cells by endocytosis 
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Genetics of secretory pathway 
The perforin gene (PRF1) consists of three exons (Figure 3).  The coding sequence is 
located in the exon 2 and 3.  PRF1 is 555 amino acid protein that has a 21 amino 
terminal signal sequence, an approximately 300 amino acid region that shares 
homology to the C9 complement protein, known as Membrane Attack Complex 
(MAC) domain. Moreover there are a 36 amino acid epidermal growth factor-like 
domain and a 132 amino acid domains homologous  to the C2 domain of protein 
kinase C (Licthened 1988).  The protein contains two N-linked glycosylation sites.  
PRF1 is synthesized as an inactive form, which must be cleaved at its carboxy 
terminus, releasing approximately 20 carboxyterminal amino acids to yield the active 
form of the protein (Uellner R. et al 1997).  
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Figure 3. perforin gene and protein structure 
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Mouse model 
Perforin deficient mice remain generally healthy if maintained in a clean facility, but 
about half of the animals develop spontaneous B-cell lymphoma as they age (almost 
invariably beyond one year of age).  Mice that are infected experimentally with 
lymphocytic choriomeningitis virus have a remarkably similar disease course to 
FHLH patients, with absent NK-cell response and anti-viral cytotoxic T-
lymphocytes activity, hepotosplenomegaly and elevation of circulating cytokine 
levels in the setting of uncontrolled viaremia. 
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Perforin, immunoregulation and autoimmunity 
Perforin-deficient mice have essentially normal immune homeostasis. For example, 
perforin deficiency impairs neither the rejection of grafted lymphocytes (Barchet W 
et al 2000) nor the in vivo homeostasis of DCs (Ludewig B. et al 2001).  However, 
considerable evidence indicates a pivotal role for perforin in immunoregulation in 
situation of immune-system disturbance caused by microbial infection, 
autoimmunity or loss of other cell death pathways.  For example, as in perforin-
deficient gld (FasL defective) mice (Spielman J. et al 1998), several studies have 
shown recently that perforin regulates the elimination of CD8+T cells after an acute 
exposure to foreign antigen.  Notably, perforin deficient mice have an increased 
clonal expansion and persistence of superantigen and virus specific T cells that could 
not be reproduced by inibhiting the elimination of antingen presenting cells perforin 
sufficient mice. (Kagi D. et al 1999)  These findings and the increased clonal 
expansion of alloreactive perforin deficient T cells after their transfer into irradiated 
scid/scid mice (which lack T and B cells), strongly support a role for perforin in the 
activation induced cell death process.  (Spaner D. 1999)  In a GVHD model, perforin 
had an important regulatory role in the prevention of humoral autoimmunity thorouh 
the elimination of both autoreactive B cells and antigen specific T cells (Shustov A. 
2000).  Following on from previously studies by Binder et al., Maltoubian et al 
showed that perforin is involved in the down-regulation of T-cell response during 
chronic LCMV infection.  (Binder D et al 1998, Matloubian M. et al 1999). All 
together, these studies support the notion of an intrinsic role of perforin in regulating 
the expansion, and than the contraction, of CD8+ T cell populations after infection.  
In summary, the data support the existence of a perforin dependent mechanism that 
regulate the extent of CD8+ cell clonal expansion in models as diverse as acute 
bacterial infections, GVHD and DC immunization.  However, this regulatory process 
might depend on the nature of the stimulus, including pathogen virulence or strength 
of stimulation, and might be influenced by other genetic factors.    
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Haemophagocytic Lymphohistiocytosis 
The Haemophagocytic Lymphohistiocytosis (HLH) (OMIM#26770) is a rare, 
congenital immune deficiency that occurs in the infants  and young children.  The 
disease usually presents with unexplained fever, malaise and failure to thrive, in the 
context of marked hepatomegaly associated with pancytopenia, htpertrigligeridemia 
and hypofibrinogenemia.  Histologically, infiltration of lymphocytes and histiocytes 
with haemophagocytic activity are seen in the reticuloendothelial system, bone 
marrow and some times in the central nervous system (Loy TS et al 1991, Janka GE, 
et al 1983, Henter J et al 1991).  Serum levels of inflammatory cytokines derived 
from activated T cell and macrophages (such as IFN-γ, TNFa, IL-1 and IL-6) are 
markedly elevated. (Table II)  
Clinical and Immunological features of patients with HLH 
Hepatosplenomegaly 
Fever 
Lyphoadenomegaly 
Edema 
Neutropenia 
Hypertrigliceridemia 
Hyperferritinemia 
Hypoalbuminemia 
Hypofibrinogenemia 
NK cell defect 
Elevated levels IFN-γ, TNF, IL-1 and IL-6 
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The presentation might be preceded by overt viral infection, but there is no direct 
relationship with any specific pathogen.  The most consistent immunologic 
abnormality reported in these patients has been the impairment of cytotoxic function 
mediated by PRF1/granzyme.  It has been observed that most patients with HLH 
have normal numbers of B lymphocytes and normal immunoglobulin levels and a 
normal absolute lymphocyte counts (Egeler RM 1996).  On the basis of numerous 
genetic studies, it has been shown that PRF1 is mutated in approximately 30% of the 
cases of the autosomal recessive form (Aricò M. et al 1996; Stepp SE et al 1999).  
More than 20 mutations have been identified in worldwide patients (Ericson K et al 
2001; Clementi R et al 2001; Suga N et al 2002; Kogawa K et al 2002; Feldmann J 
et al 2002; McCormick J et al 2003).  So far, most of the variants studied have been 
associated with either non detectable or extremely low levels of PRF1 expression in 
NK cells.  These studies led to an important issue concerning on the correlation 
between genotype and phenotype.  Although several reports greatly contributed to 
the understanding of the clinical features and the pathophysiology of the disease, 
(Henter JI et al 1998; Fujiwara F et al 1993; Janka GE 1983; Henter JI 1991; 
Imashuku S et al 1996) several aspects still need to be clarified.  In particular, it 
remains to be defined which are the functional and the biochemical abnormalities in 
the asymptomatic phase, and what are the roles, if any, of different viruses in 
triggering the overt phase of the disease. 
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Comparison of molecular, clinical, and biochemical features in a family affected 
by HLH 
During the first year of the activity our interest has been focused on the study of a 
family of six members in which one of these was affected by an overt HLH.  In 
particular,  first aim of our study was to identify any predictive clinical signs of the 
overt disease, to evaluate and compare the biochemical, functional and molecular 
features of all family members including still unaffected subjects with same 
genotype. 
 The proband presented at the age of 13 years with persistent fever, 
hepatosplenomegaly, cytopenia, and lymph node enlargement.  Biochemical 
investigation revealed hypertiglyceridemia, hypofibrinogenemia and 
hyperferritinemia.  Signs of hemophagocytosis on a liver biopsy specimen led to a 
temptative diagnosis of HLH.  Very interesting, before the overt manifestation of 
disease the proband successfully cleared from a few viral infections, such as Herpes 
Simplex virus I (HSV I), Rubella virus and Morbilli Virus.  The molecular analysis of 
the PRF1 gene revealed the presence of 2 mutations.  We found a C->T (C272T) 
homozygous substitution in exon 2 leading to an A91V amino acid change and a G-
>A (G695A) heterozygous substitution in exon 3 leading to an R231H change. 
(Figure 4 ) 
The first mutation was already reported in similar patients with HLH 
(Clementi R et al 2001), while the R231H represents a novel variant. Sequence 
analysis of all family  members revealed the presence of the A91V at the 
heterozygous status in both parents, in old sister and brothers.  Interestingly, her 
asymptomatic fraternal twin sister had the mutation at homozygous status the sister 
whit the overt disease as depicted in figure 5 in as showed in the figure 4.  The 
R231HG was found at the heterozygous status in the father and in healthy twin. 
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Figure 4.  Family pedigree and PRF1 sequence analysis. 
Pedigree of the family members indicating the subjects carrying the Ala91Val 
mutation of PRF1 gene at the homozygous (closed circles) or at the heterozygous 
(half circles) status.  The proband is indicated by the arrow.  The PRF1 sequence 
analysis revealed the presence of C3545T (causing the Ala91Val missense mutation) 
at the homozygous status in the proband and her  twin sister and at the heterozygous 
status in the other family members.  Furthermore, an additional G5150A mutation 
(causing the Arg231His missense mutation) at the heterozygous status was found in 
the proband and in the father. 
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Our subsequent step was to evaluate and compare in all family members the function 
of cytotoxicity through a cytotlytic assay.  NK activity was normal in all family 
members, including the asymptomatic twin carrying the same genetic alteration of 
the proband (Figure 5).   
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Finally the laboratory findings showed that all family members are healthy and the 
clinical history were negative (Table II).    
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Table II. Clinical and laboratory features 
 Proband Tween 
sister 
Brother Sister Father Mother 
Hepatosplenomegaly + - - - - - 
Fever + - - - - - 
Skin rash - - - - - - 
Lyphoadenomegaly + - - - - - 
Oedema + - - - - - 
CNS Involvement - - - - - - 
Platelets (x1000/mm3)         39       281       302       214        211        245 
Hemoglobin (g/dl)    4.1   12.1   11.4   14.5    15.7   12.2 
Neutropenia - - - - - - 
Hypertriglyceridemia + - - - - - 
Hypofibrinogenemia + - - - - - 
Hyperferritinemia + - - - - - 
Hypoalbuminemia + - + + + - 
Hypertransaminasemia + - - - - - 
Hyponatremia - - - - - - 
Associated Infections     EBV,CMV, 
HSI,II 
EBV, 
HSI,II 
EBV, 
HSI,II 
EBV, 
HSI,II 
EBV, 
HSI,II 
EBV, 
HSI,II 
HS = Herpes Symplex virus       
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Conclusive remarks 
In this first preliminary study we identified two mutations one of this the A91V 
occurs in a most important domain, the membrane attack complex that is needed 
for the binding of the molecule to the membrane of the cells.  Remarkably, the 
same mutation (A91V and R231H) was found in the two twins, only in one case 
it being associated with delayed clinical presentation.  Moreover, the 
comparison of the clinical history of these subjects revealed that they share 
several similarities with regard to the encountered viral agents.  In fact, the 
healthy sister had a normal clinical course during several infections, including 
an Epstein Barr virus (EBV) infection, which usually considered a triggering 
factor (Kogawa K et al 2002).  So the first conclusion is that virus-derived 
products are not sufficient per se to determine the accelerated phase of the 
disease.  Furthermore,  the functional studies in 2 twin sisters have shown that 
NK activity was normal in the healthy sister and severely impaired in the 
proband.  Emerging evidence has indicates that a reduction of NK activity in 
some heterozygous subjects for this  mutation supports the hypothesis  of a 
partial dominant-negative effect of few mutations.  Moreover, in a few patients, 
NK activity was initially normal and subsequently decreased, thus implying that 
additional genetic factors may interfere with the immune function.  The 
molecular mechanism that underlies the different clinical and functional 
behavior of the disease in the 2 subjects here described remains to be clarified.  
It is possible that further genetic alterations may interfere in the phenotypic 
expression of the disease and moreover, we cannot exclude with certainty that 
the fraternal twin could develop the disease in the future.  These results have 
been published on the Blood journal  (see below the attached paper) 
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Definition of the pathogenic role of the molecular alterations in PRF1 in 
patients with Haemophagocytic Lymphohistiocytosis 
In the second part of our project we have continued to study the important issue 
of difficult correlation between genotype/phenotype correlation in HLH disease.  
In particular our interest has been focused on the A91V and on its discussed 
pathogenic role in HLH.  This mutation has been described either as disease 
causing mutation by our group and (Clementi R et al 2001) either as not 
associated to overt disease in some subjects not affected by HLH.  Our 
previously published data, in which the mutation was described in 2 twin sister, 
one affected by FHLH and one with completely healthy phenotype, led us to 
hypothesize that along with the A91V mutation other factors may interfere in 
the clinical expression of the disease. At this phase of the study at the aim  to 
better clarify the role of the A91V mutation in the pathogenesis of HLH we 
perform a biochemical and functional study of NK activity in subjects carrying 
the A91V mutation at the heterozygous status among the relatives of affected 
probands from our geographic area.  All research subjects were asymptomatic 
and cleared normally from common viral infection.  Furthermore, all subjects 
have normal biochemical parameters, including fibrinogen, triglycerides and 
ferritin values.   As shown by Figure 6, all research subjects carrying the A91V 
alterations at the heterozygous status showed a normal NK activity.  These 
findings have been published on the Blood journal see bellow for the attached 
paper.   
At this state of the project we propose the A91V alteration as a molecular 
variant that is not per se causative of the disease, and very importantly not 
sufficient to impair the cytolytic activity.   
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This study has been published on Blood journal, see below the attached 
manuscript.  
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A91V PRF1 variation in healthy subjects and FHLH patients 
Our previously published observation of a normal NK function in 9 subjects 
with A91V mutation at the heterozygous status seem to be consistent with a 
non-pathogenic role in the HLH.  A summary of literature is in keeping with this 
observation, this mutation was described, either as a frequent polymorphism, 
present in 9% of healthy subjects (Feldmann 2002; zur Stadt 2004) or as a 
possible disease causing mutation in two families of patients with late onset 
disease (Clementi 2002; Busiello 2004).  Additionally, Lee et al observed a 3% 
(7/202) frequency of this transition in a cohort of controls.  Taken together, 
these observations leave open the discussion on the pathogenic role of the A91V 
mutation in FHLH.  So in the effort to make a conclusive remark to this issue we 
examine the distribution of this mutation in populations originating from 
different geographic areas and compare the genetic results.  In this phase of 
study, we evaluated the allelic frequency of A91V mutation in a group of 
families recruited through the “Centre d’Etude du Polymorphisme Humain” 
(CEPH) representative of the worldwide population. 
(http://www.genlink.wustl.edu/cephv8/ceph.html)  The frequency was also 
compared with that observed in FHLH patients in association with PRF1 gene 
alterations, recruited through the FHLH Italian Registry.  A total of 82 DNA 
samples from 41 unrelated healthy families of the “Centre d’Etude du 
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Polymorphism Humain” were obtained from the Foundation Jean Dausset, Paris.  
All these samples were analyzed to estimate the allelic frequency of A91V 
mutation in the PRF1 gene.  Moreover, molecular information of 21 subjects 
with FHLH and PRF1 gene alteration was obtained from the Italian Registry of 
FHLH.  As shown in the Table III, the sequence analysis revealed the presence 
of the A91V mutation at the heterozygous state in 6 out of 82 subjects belonging 
to CEPH families (6/164 chromosomes; 3.7%).  In the patients affected with 
FHLH associated with a molecular alteration of PRF1 gene recruited through 
the FHLH National Registry, this transition was present in 10 out 21 patients.  
A91V transition was present always at the heterozygous state, but in an 
individual patient who carried the mutation at the homozygous state (11/42 
chromosomes 26.2%).  This frequency was significantly higher than that 
observed in CEPH families (p = 0.0002).  The observed frequency in the CEPH 
families is in keeping with the reported frequency in North American healthy 
population (Molleran Lee 2004) (3%) and is representative of the worldwide 
genomic variation and was also in keeping with frequency of 3.9% described in 
our area, reported by Trambas et al 2005 in (see the table III).  
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 Patients Our Area Italian 
control  
CEPH 
A91V 
frequency 
26.2% 3.9% 3.7% 3.7% 
A91V variation 
and  other 
mutations 
100% -  - 
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Moreover, as illustrated in the Table III, in the patients with FHLH and PRF1 
mutation, the A91V transition is always present in association with another 
molecular alteration of PRF1 gene, whereas in the CEPH families the transition 
is always isolated.  This is also in keeping with the observation that none of the 
reported FHLH patients have the A91V mutation in the absence of any other 
PRF1 alteration (Molleran Lee 2004).  Taken together, these results support the 
hypothesis that A91V may represent a frequent molecular alteration, which is 
not causative “per se” of FHLH and not sufficient to abolish cytolytic activity.   
However, the higher frequency of the A91V substitution in FHLH patients with 
at least one additional PRF1 mutation supports a role for this mutation as a 
strong susceptibility factor, contributing to the pathogenesis of the disease.  
Whether this effect is mediated by a synergic effect with other PRF1 alterations, 
remains to be elucidated.  These data has been submitted to International  
journal of Immunogenetics and are in course of revision see below for the 
manuscript.   
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Molecular defects in human Severe Combined Immuodeficiency  
Severe Combined Immunodeficiencies (SCID) are a genotypically and 
phenotypycally heterogeneous group of disorders characterized by severe defect 
of both T- and B-cell immunity.  These form are in generally fatal within the 
first years of life, although a few typical cases may be characterized by a milder 
phenotype.  These set of different disease share common clinical features, such 
as high susceptibility to develop severe and, sometimes, fatal infections (Fisher 
1997; Kokron 1997).  Thus far, all the different forms  with a known molecular 
basis are caused by mutations in genes expressed in the hematopoietic system, 
which lead to intrinsic abnormalities of lymphocytic function.  Our group in  
1999 described a novel form of SCID (MIM 601705) which represents the 
human equivalent of the well known murine phenotype defined Nude/SCID 
(Pignata et al 1996).  This form is the only human SCID caused by intrinsic 
abnormality of the epithelial component of the thymus (Pignata et al 1996).  The 
gene responsible for the disease in both mice and humans encodes the 
forkhead/winged helix (WHN) FOXN1 transcription factor selectively 
expressed in thymic epithelia and skin (Nelse et al 1994, Segre et al 1995 Frank 
et al 1999).  The most prominent clinical features is a congenital alopecia, from 
which the term “Nude” for the murine equivalent derived (Flanagann 1996) 
furthermore the disease is associated to a profound T cell defect.  The first 
human molecular alteration was a C792T transition in exon 5 resulting in the 
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nonsense mutation R255X (Frank 1999).  To date, the first 2 patients 
investigated, carrying the R2554X mutation in the homozygous status, were 
born to consanguineous parents originating from small community in southern 
Italy (Pignata et al 1996).   
Molecular screening for the R255X alteration in isolated population 
In this phase of research based on the presence of several cases in the 
community, genetic screening for the presence of the FOXN1 R255X mutation 
was performed in an attempt to identify an ancestral founder effect.  In fact due 
to the geographical location of the village, lying in the mountains between 
Naples and Salerno, and the elevated rate of endogamy, the population may be 
considered isolated.  Moreover, we have genotyped 2 microsatellite markers, 
D17S2187 and D17S1880 flanking the FOXN1 gene on chromosome 17 to 
define whether a founder chromosome is shared by individuals carrying the 
R255X mutation.  Molecular analysis revealed that 55 subjects, corresponding 
to 6.52% of the population were found heterozygous carriers of the mutation.  In 
these 55 subjects, originated from 39 families, we perform a genealogical study.  
Through the archival database, common ancestors were identified for the 55 
heterozygous carriers.  They are linked in an extended 7 generational pedigree 
comprising 483 (Figure 8) individuals founded by a single ancestral couple born 
in 19th century.  
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This work has been very important also to give a prenatal diagnosis support to 
this population.  These results has been published on the Annals of Human 
Genetics see below for the manuscript. 
  
61 
61 
References  
1.  Festing, M. F. W., May, D., Connors, T. A. et al. (1978) An athymic nude 
mutation in the rat. Nature  274, 365-366. 
2.  Fischer, A., Cavazzana-Calvo, M., De Saint Basile, G. et al. (1997) 
Naturally occurring primary deficiencies of the immune system. Annu Rev 
Immunol  15, 93-124. 
3.  lanagan, S. P. (1966) 'Nude', a new hairless gene with pleiotropic effects 
in the mouse. Genet Res  8, 295-309. 
4.  Frank, J., Pignata, C., Panteleyev, A. A. et al. (1999) Exposing the human 
nude phenotype. Nature  398, 473-474. 
5.  Hofmann, M., Harris, M., Juriloff, D. et al. (1998) Spontaneous mutations 
in SELH/Bc mice due to insertions of early transposons: molecular 
characterization of null alleles at the nude and albino loci. Genomics  52, 
107-109. 
6.  Huth, M.,  Schlake, T. &  Boehm, T. (1997) Transposon-induced splicing 
defect in the rat nude gene. Immunogenetics  45, 282-283. 
7.  Kokron, C. M., Bonilla, F. A., Oettgen, H. C. et al. (1997) Searching for 
genes involved in the pathogenesis of primary immunodeficiency 
diseases:  lessons from mouse knockouts. J Clin Immunol  17, 109-126. 
8.  Miller, S. A.,  Dykes, D. D. &  Polesky, H. F. (1988) A simple salting out 
procedure for extracting DNA from human nucleated cells. Nucleic Acid 
Res  16, 1215. 
9.  Nehls, M., Pfeifer, D., Schorpp, M. et al. (1994) New member of the 
winged-helix protein family disrupted in mouse and rat nude mutations. 
Nature  372, 103-107. 
 
  
62 
62 
10.  Pignata, C., Fiore, M., Guzzetta, V. et al. (1996) Congenital Alopecia and 
nail dystrophy associated with severe functional T-cell immunodeficiency 
in two sibs. Am J Med Genet  65, 167-170. 
11.  Segre, J. A., Nemhauser, J. L., Taylor, B. A. et al. (1995) Positional 
cloning of the nude locus: genetic, physical, and transcription maps of the 
region and mutations in the mouse and rat. Genomics  28, 549-555 
  
63 
63 
 
  
64 
64 
 
  
65 
65 
 
  
66 
66 
 
  
67 
67 
 
Nail dystrophy associated to heterozygous mutation of the Nude/SCID 
FOXN1 gene.   
In this phase of the project our group focusing the attention on several clinical 
features such as ectodermal defects.  In particular, alopecia and nail dystrophy 
and thymic aplasia which are main features of the Nude/SCID.  The program led 
us to physical examination of the 55heterozygous subjects with a special 
attention to ectodemal abnormalities (hair and nails alterations).  Since FOXN1 
seems to play a key role in the regulation of the differentiation process of both 
cutaneous and thymic epithelial tissue (Lee D, et al 1999).  The cutaneous 
annexa were analysed at least 2 of us in the 55 heterozygotes, in 23 non 
heterozygous healthy married-in subjects, and 50 non heterozygous subjects 
belonging to the extend pedigree.  Our analysis reveal that in 39 out of 55 
heterozygous subjects showed a nail dystrophy.  This association between nail 
dystrophy and heterozygous mutation of FOXN1 gene  is for the first time 
reported.  Moreover these findings is in keeping with the alteration of the digits 
and nails reported in a few strains of nude mice (Lee D, et al 1999) Our findings 
confirm that this transcriptions factor is involved in the maturation process of 
nails.  These data has been published on Archives of Dermatology see below for 
the attached paper.  
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Ectodemal defects, such as alopecia and nail dystrophy, and thymic 
aplasia are the main features of the spontaneous immunodeficient mouse 
strain, referred as Nude/SCID.  The human equivalent of the Nude/SCID 
phenotype, has been recently described in 2 children affected with a 
predominant T-cell defect associated with congenital alopecia and nail 
dystrophy.1  In humans, as already reported in mice, the disease is due to a 
molecular alteration of the transcription factor FOXN1 (previously WHN),2 
which is selectively expressed in thymic and cutaneous epithelia.  In 1999, a 
screening search for FOXN1 mutation was undertaken in the community 
where the probands originated from to ensure to the population genetic 
counseling and prenatal diagnosis support.  This program led to the identify 
55 subjects carrying the FOXN1 mutation at the heterozygous status all 
belonging to the same extended pedigree as above reported.3 
Physical examination of the identified heterozygous subjects was 
conducted paying a special attention to ectodermal abnormalities and, in 
particular, to alterations of hair and nails in order to define whether the 
heterozygousity was associated with mild clinical signs.  Since Foxn1 seems to 
play a role in the regulation of the differentiation process of both cutaneous and 
thymic epithelial tissues,4 these annexa were analysed by at least 2 of us in the 
  
71 
71 
55 heterozygotes, in 23 non heterozygous otherwise healthy married-in subjects, 
and 50 non heterozygous subjects belonging to the extended pedigree.   
No gross alteration of the hair was noted in association with the 
heterozygousity.  Differently, nail examination revealed that 39 out of the 55 
heterozygous subjects showed a nail dystrophy.  This finding was not observed 
in any of the other control groups and was not related to an acquired form of nail 
dystrophy.  Whenever necessary, cultures were performed to rule out mycotic 
infections.  An accurate anamnesis was performed for each individual to 
evaluate any systemic disease able to induce nail dystrophy.  Overt psoriasis was 
also excluded.  However, the pattern of the phenotypic alteration of the nails 
was variable as shown in the  Figure 1A-C.  The koilonichia or "spoon nail" 
characterised by a concave surface and raised edges of the nail plate associated 
with a significant thinning of the plate itself was the more frequent alteration.  
As summarised in the Table, it was found in 28 subjects, whereas the canaliform 
dystrophy and a transverse groove of nail plate (Beau's line) were found in 13 
and 11 subjects, respectively.  It is note worthy that the more specific 
phenotypic alteration was the leukonychia characterised by a typical arcifom 
pattern, involving the proximal part of the nail plate reminiscent of the half-
moon.  This is not surprising since it reflects an abnormal differentiation process 
of the cells of the matrix.  Seventeen out of the 39 heterozygotes with nail 
dystrophy had 2 or more features.  It should be noted that in 18 cases fingernails 
  
72 
72 
and toenails were both affected, whereas in 4 subjects the dystrophy was only 
observed in the feet. 
 Herein, is for the first time reported in humans on the association between 
nail dystrophy and heterozygous mutation in the FOXN1 gene.  This finding 
is in keeping with the alterations of digits and nails reported in a few strains 
of nude mice.4  Since the nail plate originates mainly from the nail matrix and 
FOXN1 is selectively expressed in such structure, our observation confirms 
that this transcription factor is involved in the maturation process of nails, and 
suggests that this sign may be indicative of heterozygousity for this molecular 
alteration. 
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Table.  Pattern of nail dystrophy in R255X heterozygous subjects 
Nail alteration localizzation 
  
 
Pattern of Nail 
dystrophy 
 
N° of 
Patients 
Hand Foots 
Leukonychia 6 5 3 
Koilonychia 28 23 18 
Canaliform   
Onycodystrophy 
13 12 2 
Beau’s line 11 10 6 
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Clustering of Autoimmune Disease (CAD): identification of a novel clinical 
entity 
The exisistance of novel clinical phenotype characterized by a Clustering of 
Autoimmune Disease in an individual has been recently documented.  In 
particular, was been identified several subjects characterized by the presence of  
distinct autoimmune disorders which are indicative of a common polyreactive 
autoimmune process (Rieux-Laucat et al 2003).  The abnormal function of one 
of two distinct pathway of apoptosis, the secretory and non-secretory pathway 
represents the pathogenic mechanism by which these subjects may develop 
hyperimmune diseases  and syndromes with severe and complex  clinical 
phenotype.  A Mendelian transmission for some of these complex phenotype 
has been documented, in particular, for Autoimmune Polyendocrinopathy 
Candidiasis-Ectodermal Dystrophy (APECED) (Neufeld et al 1980), (APECED) 
Immunodysregulation, Polyendocrinopathy, Enteropathy, X linked syndrome 
(IPEX) (Wildin et al 2002) and Autoimmune Lymphoproliferative Syndrome 
(ALPS) (Canale et al 1967).  The last one represents a prototype of CAD.  
Recent evidence indicates that, in a few cases, CAD may represent an unique 
model of monogenic autoimmune disorder (Fischer et al 2004).  Hematologic 
autoimmune disorders associated with nonmalignant lymphadenopathy are the 
prominent clinical features of the ALPS, whose molecular characterization led to 
define five distinct entities on the basis of the location of the defect in the Fas 
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signaling cascade (Rieux-Laucat et al 2003).  The ALPS0 represents the human 
analog of the lpr mice (Fas-/-) and is associated to a complete absence of Fas 
molecule.  The ALPSIa, represents the most frequent form of the syndrome and 
is associated to heterozygous mutation of Fas gene.  The ALPSIb is associated 
to a molecular alteration of the ligand of Fas, FasL while the ALPSII is 
associated to an alteration of the caspase 10 gene.  Moreover, ALPSIII 
represents a large group of ALPS patients in which the molecular defect still 
remains to be identified.  Along with typical form of this syndromes in several 
form, ALPS-like the autoimmune process is associated to an immunodeficit 
which leads to an increase susceptibility to viral infection.  In a recent study, a 
novel form of ALPS  has been identified.  This form is characterized by a 
specific immunodeficit of T, B and NK lymphocytes and is associated to an 
alteration of caspase 8 gene.  (Lenardo et al 2002)  Aim of this phase of the 
project was been to characterize the phenotypic and immunological features of 
consecutive patients affected with CAD and to contribute to define the familial 
pattern of inheritance and clinical expression.  In particular, we have focused on 
the evaluation of the functional integrity of Fas/FasL pathway, on the evaluation 
of the presence of immune defect and finally on the molecular analysis of 
caspase 8 gene.  In this study has been identified 23 patients, affected by three 
or more autoimmune disorders.  In the overall group of patients, 18 out of 23 CAD 
patients (78%) had a positive familial history.  Within the probands’ family 
  
77 
77 
members group, 56 subjects were affected with at least one autoimmune 
disorder.  The analysis of the pedigrees of the familial cases showed that the 
character of autoimmunity was inherited through the maternal lineage in the 
22.2 % and through the paternal lineage in the 38.8 % of cases.  In the 38.8 % of 
families an autoimmune phenotype was present in both lineages.  Analysis of 
Fas-induced cell death in PHA-derived T cell lines detected defective apoptosis 
in 14 out of the 23 CAD patients (60%).  Fas expression was evaluated in the 
long-term T cell lines by direct immunofluorescence on the same day in which 
Fas function was assessed and was expressed always at comparable levels than 
in controls.  No relationship between abnormal Fas-induced cell death and either 
anticipation or the higher severity in the probands’generation was found.  In the 
14 patients with defective Fas-induced apoptosis, we searched for mutations of 
the Fas gene.  Direct sequencing revealed a 2 base deletion in exon 4 (g410-
411delCT) in one patient (Pt # 14).  In other patients, we found several DNA 
changes which did not result in amino acid substitution.  In particular, we found 
6 different polymorphisms, 2 of them falling in the 5’ UTR region, 2 mapping in 
the coding region, and 2 in the intronic region (IVSIII nt 46, IVSV nt 82).  All 
these polymorphisms were already described. Direct sequencing of caspase-8 
gene failed to identify causative mutations and revealed 3 already described 
polymorphisms: 2 mapping in the exon 9, and 1 in the intronic region (IVSIX nt 
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1123). This study has been submitted for publication to Journal of Clinical 
Immunology, see below for the manuscript.  
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Primary Immunodeficiency Disease as models of immune system 
homeostasis: a literature survey 
In the final part of our project we have considered several immune deficiency 
characterized by an alteration of the homeosataic mechanism caused by an 
aalteration of central or peripheral tolerance.  In particular, we have focused our 
attention to syndromes such as Autoimmune Polyendocrinopathy Candidiasis-
Ectodermal Dystrophy (APECED) (Neufeld 1980), (APECED) 
Immunodysregulation, Polyendocrinopathy, Enteropathy, X linked syndrome 
(IPEX) (Wildin 2002) and Autoimmune Lymphoproliferative Syndrome 
(ALPS) (Canale 1967).   
APECED  
APECED is characterized by the variable occurrence of T cell and B cell 
mediated autoimmune diseases targeting various endocrine glands  (parathyroid, 
thyroid, adrenal glands, gonads, pancreas, liver, skin and erythrocytes).  It is 
often associated with chronic mucocutaneous candidiasis and ectodermal 
dysplasia  (Fisher 2004).  It is inherited as a Mendelian disease with an 
autosomal recessive mode. Loss of function mutations in Autoimmune 
Regulator gene (AIRE) cause the disease (Fisher 2004).  A similar phenotype 
has been noted in Aire-/- mice (Fisher 2004).  Considerable interest was sparked 
by the fact the AIRE is expressed mainly in medullary thymic epithelial cells 
and that the gene encodes for a protein  with a DNA binding activity and gene 
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transactivation capacity (Fisher 2004).  Recently, several reports have 
demonstrated that AIRE actually regulates the ectopic expression in medullary 
thymic epithelial cells of tissue specific proteins normally found in  terminally 
differentiated organs, such as preproinsulin and zona pellucida glycoprotein 3 
(Fisher 2004).  These results strongly indicate that AIRE expression is key in 
central tolerance to a set of self proteins, although the mechanism by which 
AIRE triggers their gene expression is still unknown.  
IPEX 
The IPEX syndrome is a multisystemic autoimmune disease with an early onset 
and often fatal outcome (Fisher 2004).  Severe enteropathy with diffuse and 
massive T cell infiltration and mucosal destruction variably associated with 
diabetes, eczema and autoimmunity toward blood cells are hallmarks of this 
disease.  Loss of function mutations in the gene Foxp3 are causal (Fisher 2004).  
Foxp3 encodes a DNA binding  protein of the forkhead family with a winged 
helix domain.  It is expressed mainly by a subset of regulatory CD4 T cells that 
also express CD25 (Fisher 2004).  There is a similar natural mutant in mice : the 
scurfy mice (Fisher 2004).  As foxp3 is essential for regulatory  T cell induction, 
this phenotype seems to be the consequence of a deficiency in regulatory T 
cells.  The dominance of normal over mutated cells in obligate carriers and after 
bone marrow transplantation, respectively, results in a mixed chimerism (Fisher 
2004).  The IPEX phenotype differs from APECED and these differences 
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demonstrate the nonredundancy of the mechanism controlling autoimmune 
disease.  (Figure 7) 
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Immune System and Endocrine System a crosstalk between  complex  
systems  
The crosstalk between Nervous System (NS), Endocrine System (ES) and 
Immune System (IS) has been documented.  Recently, a large number of 
experimental evidences show a tight interaction between IS and ES.  In 
particular, the growth hormone as GH and IGF-I which play a key role in the 
growth and in the tissue metabolism seems to play a key role in the maintenance 
and in homeostasis of IS.  However the mechanism of action and the role of 
production by leucocytes of hormones with an endocrine function still to be 
clarified.   The aim of this phase of this research project is to clarify the 
biochemical and molecular mechanism of the of the network of  ES and IS and 
to clarify if  an alteration of this complex network may be implicated in the 
pathogenesis of Congenital Immunodeficiency (CID).  Severe combined 
immunodeficiencies (SCIDs) represent a wide spectrum of illnesses, which 
differ in either the qualitative or quantitative alterations of T-, B- and natural 
killer- (NK-) cell (Fischer et al  1997).  Most forms of SCID are associated with 
molecular alterations of genes selectively expressed in hematopoietic cells and 
implicated in cell differentiation/activation process.  Thus, classical symptoms 
are generally considered those related to the immunological impairment that 
results in increased susceptibility to infections.  Since patients usually die by the 
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first year of age without an effective treatment, the clinical phenotype is 
predominated by the life-threatening problems.   
Functional Interaction of Common Gamma Chain and Growth Hormone 
Receptor Signaling Apparatus  
X-linked SCID (X-SCID) is the most common form of the disease 
accounting for approximately half of all cases (Noguchi et al 1993; Leonard et 
al 2001).  The gene responsible for X-SCID is IL2RG that encodes for the 
common cytokine receptor γ chain (γc), a member of the cytokine receptor class 
1 superfamily.  The molecule represents a shared component of several 
receptors critical for the development and function of lymphocytes (Leonard et 
al 2001).  To our knowledge, an extrahematopoietic role of γc has not yet been 
demonstrated, although the abundance of the protein in non-hematopoietic cells 
would imply additional functions for this element (Du et al  2005; Ozawa et al  
2004).  We previously reported on a patient affected with a X-linked Severe 
Combined Immunodeficiency (X-SCID) who received a BMT late at 5.2 years 
of age.  In this patient, short stature became evident, and a peripheral GH 
hyporesponsiveness associated with abnormalities of the protein 
phosphorylation events that occur following GH receptor (GHR) stimulation 
were demonstrated.   The GHR was the first identified member of the cytokine 
receptor class 1 superfamily, which includes receptors for Erythropoietin (EPO), 
Granulocyte colony stimulating factor (G-CSF), Granulocyte-macrophage 
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colony stimulating factor (GM-CSF), Interleukins- (IL-) 2-7, IL-9, IL-11, IL-12 
and many other cytokines.  Due to the lack of intrinsic kinase activity, members 
of the cytokine receptor superfamily recruit and/or activate cytoplasmic tyrosine 
kinases to relay their cellular signal.  The Janus associated kinase 2 (JAK2) 
represents the predominant non receptor tyrosine kinase required for the 
initiation of GH signal transduction upon ligand binding to the receptor 
(Argetsinger et al  1993; Zhu et al  2001).    Signal transduction through GHR 
also involves a wide array of molecules, such as Signal Transducers and 
Activators of Transcription (STATs) 1, 3 and 5, Extracellular regulated kinase 1 
and 2 (ERK1 and 2) and Phosphatidylinositol-3 kinase-protein kinase B (Zhu et 
al 2001).  Activation of STAT5b is considered a prominent event in GH 
signaling and is crucial for the regulation of transcription of GH-responsive 
genes, including the gene encoding for insulin-like growth factor-I (IGF-I), 
which mediates many of the GH biological functions (Clark et al  1997; 
Dorshkind et al 2000; Le Roith et al 2001).  In our previous study, mutational 
screening and expressional analysis failed to reveal any molecular alteration of 
GHR, JAK2 and STAT5A/B genes in the patient with X-SCID and peripheral GH 
hyporesponsiveness (Ursini et al 2002).   
Since we hypothesized a role for the γc chain in GHR signaling, in this study, 
we evaluate the functional interaction between GHR and the common γ element 
in either freshly isolated or Epstein-Barr virus (EBV) transformed lymphocytes 
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from X-SCID patients and healthy subjects.  In particular, the functional 
response to GH stimulation, the pattern of GHR induced protein tyrosine 
phosphorylation and GH induced translocation from the cytoplasm to the 
nucleus of STAT5 were evaluated.  We demonstrate the existence of a 
previously unappreciated functional interaction between γc and GHR.  This 
interaction leads to the activation and intranuclear translocation of STAT5b 
protein.  The preliminary results showed in the control subjects a 
phosphorilation of STAT5B after GH stimulation while in the cells of the 
patients was not present.  Moreover in the cellular line gc- there wasn’t any 
nuclear migration of STAT5B after GH stimulation while in the cells of the 
control subjects the migration was possible after 30 min of GH stimulation.  Our 
study demonstrates the existence of a previously unappreciated relationship 
between individually well studied elements, such as GHR and γc, and signaling 
pathways.  Crosstalk between receptor signaling systems is now emerging as an 
important and exciting area of signaling research.  These results has been 
submitted for publication to Journal of  Immunology. 
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Abstract 
We previously reported on an X-linked SCID patient, who also had peripheral growth 
hormone (GH) hypo-responsiveness and abnormalities of the protein phosphorylation 
events following GH receptor (GHR) stimulation.  In the present study, we examined a 
potential role of common cytokine receptor γ chain (γc) in GHR signaling using EBV 
transformed lymphocytes from healthy subjects and γc negative X-SCID patients.  We 
demonstrated that the proliferative response to GH stimulation of γc negative patients 
B-cell lines was impaired despite a comparable cellular expression of GHR molecules to 
controls.  In patients, after GH stimulation no phosphorylation of STAT5 was observed.  
In addition, the molecule localization through confocal microscopy revealed that in 
patient’s B-cell lines no nuclear translocation of STAT5b following GH stimulation 
occurred differently from controls.  Biochemical analysis of the nuclear extracts of γc 
negative cell lines provided further evidence that the amount of STAT5b and its 
phosphorylated form did not increase following GH stimulation.  Our study 
demonstrates the existence of a previously unappreciated relationship between GHR 
signaling pathway and γc, which is required for the activation of STAT5b in B cell lines.  
These data also confirm that growth failure in X-SCID is primarily related to the 
genetic alteration of the IL2RG gene. 
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Introduction 
Severe combined immunodeficiencies (SCIDs)3 represent a wide spectrum of 
illnesses, which differ in either the qualitative or quantitative alterations of T-, 
B- and natural killer- (NK-) cell (1).  Most forms of SCID are associated with 
molecular alterations of genes selectively expressed in hematopoietic cells 
and implicated in cell differentiation/activation process.  Thus, classical 
symptoms are generally considered those related to the immunological 
impairment that results in increased susceptibility to infections.  Since 
patients usually die by the first year of age without an effective treatment, the 
clinical phenotype is predominated by the life-threatening problems.   
X-linked SCID (X-SCID) is the most common form of the disease 
accounting for approximately half of all cases (2, 3).  The gene responsible for 
X-SCID is IL2RG that encodes for the common cytokine receptor γ chain (γc), a 
member of the cytokine receptor class 1 superfamily.  The molecule represents a 
shared component of several receptors critical for the development and function 
of lymphocytes (3).  To our knowledge, an extrahematopoietic role of γc has not 
                                                 
3
 Abbreviations used in this paper:  GH, growth hormone; GHR, GH receptor; γc, common 
cytokine receptor γ chain; EPO, erythropoietin; IGF-I, insulin-like growth factor-I; BCLs, 
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yet been demonstrated, although the abundance of the protein in non-
hematopoietic cells would imply additional functions for this element (4, 5). 
We previously reported on a patient affected with a X-linked Severe 
Combined Immunodeficiency (X-SCID) who received a bone marrow 
transplantation (BMT) late at 5.2 years of age.  In this patient, short stature 
became evident, and a peripheral growth hormone (GH) hyporesponsiveness 
associated with abnormalities of the protein phosphorylation events that occur 
following GH receptor (GHR) stimulation were demonstrated.   
The GHR was the first identified member of the cytokine receptor class 1 
superfamily, which includes receptors for Erythropoietin (EPO), Granulocyte 
colony stimulating factor (G-CSF), Granulocyte-macrophage colony stimulating 
factor (GM-CSF), Interleukins- (IL-) 2-7, IL-9, IL-11, IL-12 and many other 
cytokines.  Due to the lack of intrinsic kinase activity, members of the cytokine 
receptor superfamily recruit and/or activate cytoplasmic tyrosine kinases to 
relay their cellular signal.  The Janus associated kinase (JAK) 2 represents the 
predominant non receptor tyrosine kinase required for the initiation of GH 
signal transduction upon ligand binding to the receptor (6, 7).  However, GH 
also stimulates tyrosine phosphorylation of JAK1 (8, 9) and JAK3 (10) in 
certain cell lines.  Signal transduction through GHR also involves a wide array 
of molecules, such as Signal Transducers and Activators of Transcription 
(STATs) 1, 3 and 5, Extracellular regulated kinase (ERK) 1 and 2 and 
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Phosphatidylinositol-3 kinase-protein kinase B (7).  Activation of STAT5b is 
considered a prominent event in GH signaling and is crucial for the regulation of 
transcription of GH-responsive genes, including the gene encoding for insulin-
like growth factor-I (IGF-I), which mediates many of the GH biological 
functions (11-13).  In our previous study, mutational screening and expressional 
analysis failed to reveal any molecular alteration of GHR, JAK2 and STAT5A/B 
genes in the patient with X-SCID and peripheral GH hyporesponsiveness (14).   
Since we hypothesized a role for the γc chain in GHR signaling, in this 
study, we evaluate the functional interaction between GHR and the common γ 
element in either freshly isolated or Epstein-Barr virus (EBV) transformed 
lymphocytes from X-SCID patients and healthy subjects.  In particular, the 
functional response to GH stimulation, the pattern of GHR induced protein 
tyrosine phosphorylation and GH induced translocation from the cytoplasm to 
the nucleus of STAT5 were evaluated.  We demonstrate the existence of a 
previously unappreciated functional interaction between γc and GHR.  This 
interaction leads to the activation and intranuclear translocation of STAT5b 
protein.   
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Materials and Methods 
Reagents 
Recombinant human growth hormone (rGH) was obtained from Serono 
(Saizer® 4).  The enhanced chemiluminescence kit (ECL) was purchased from 
Amersham Biosciences.  The antibodies anti-STAT5b, anti-STAT5a, anti-
STAT1, anti-STAT3, anti-ERK (recognizing both ERK1 and ERK2), anti-
phosphotyrosine ERK, anti-GHR and anti-γc and the monoclonal-antibodies 
anti-phosphotyrosine were purchased from Santa Cruz Biotechnology (Santa 
Cruz).  Acrylamide and bisacrylamide were from Gibco.  Prestained molecular 
weight standards were from BIORAD.  Except where noted, other reagents were 
of either reagent or molecular biological grade from Sigma.   
 
Cells and cell cultures 
Mononuclear cells (PBMC) were obtained from 4 X-SCID patients and normal 
donors heparinized peripheral blood by Ficoll-Hypaque (Biochrom) density 
gradient centrifugation.  Upon informed consent, lymphoblastoid cell lines 
(BCLs) were generated by Epstein-Barr virus immortalization of patients and 
controls PBMC using standard procedures (15).  In all cases, γc mutations led to 
the absence of protein expression.  Cells were maintained in RPMI 1640 
(Biochrom) supplemented with 10% fetal bovine serum (Gibco), 2 mmol/L L-
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glutammine (Gibco), and 50 µg/ml gentamycine (Gibco), and cultured at 37°C, 
5% CO2.   
 
Proliferative assay 
BCLs (1 X 105 cell/200 µl well) were cultured triplicate in 96-well U-bottomed 
microtiter plates (Falcon®, Becton Dickinson) with or without rGH at reported 
concentrations for 4 days.  The proliferative response was evaluated by 
thymidine uptake from cultured cells pulsed with 0.5 µCi [3H]thymidine 
(Amersham International) 8 h before harvesting (16). 
 
Flow cytometry 
The expression of GHR was detected using specific rabbit antibodies (Santa 
Cruz) by indirect immunofluorescence using a second-step incubation with a 
FITC-conjugated donkey anti-rabbit antibodies (Pierce).  After washing in PBS, 
cells were incubated for 20 min with the specific antibodies and 30 min with 
secondary antibodies.  After staining, all samples were washed in PBS and 
acquired on the FACScan flow cytometer (Becton-Dickinson) using Lysis I 
software. 
 
Cell stimulation and protein extraction 
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Prior to hormone treatment, the cells were made quiescent through incubation in 
RPMI 1640 minus serum for 8-12 h.  GH was used at 37°C at a concentration of 
500 ng/ml in RPMI 1640 for the reported time.  Incubations were terminated by 
washing cells with ice cold phosphate-buffer saline  (PBS; BioWhittaker) 
followed by solubilization in 100 µl of lysis solution containing 20 mM Tris 
(pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mmol EDTA, 1 mM 
phenylmethylsulfonylfluoride, 1 mM sodium orthovanadatum (Na3VO4), 5 
µg/ml leupeptin and 5 µg/ml aprotinin.  The cell lysates were stored at -80°C for 
Western blot analysis.  Nuclear extracts were prepared by the method of 
Andrews et al. (17) and were subsequently mixed with sample buffer. 
 
Western blot 
Immunoblotting using phosphotyrosine monoclonal antibody was performed as 
previously reported (14).  Immunoblotting using specific antibody was 
performed according to the vendors protocols.  In brief, protein samples 
separated by SDS-PAGE were transferred onto Mixed Cellulose Esters 
membranes (Immobilon-NC Mixed Cellulose Esters 0.45 µm; Millipore).  The 
membrane was incubated at room temperature for 1 h in blocking buffer 
consisting of 10% Bovin Serum Albumin (BSA) in wash buffer (10 mM Tris, 
pH 7.5, 100 mM NaCl, 0.1% Tween 20).  The membrane was then washed three 
times in wash buffer and incubated 1 h at room temperature or overnight at 4°C 
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with the specific antibody.  The membrane was then washed three times and an 
appropriate IgG horseradish peroxidase-coniugated secondary antibody was 
used for the second incubation.  After further washings, the membrane was 
developed with ECL developing reagents, and exposed to x-ray films according 
to the manufacturer’s instructions (Amersham Biosciences).   
  
134 
134 
 
Confocal microscopy 
After appropriate stimulation, quiescent cells were rinsed in ice cold PBS and 
fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.0) for 30 min at 
room temperature.  After 4 rinses of 5 min in PBS, the cells were centrifuged in 
a Shandon Cytospin III (Histotronix Inc.) onto glass slide and permeabilized by 
incubation in a 0.2% Triton X-100 solution for 20 min.  The cells were then 
incubated for 1 h at room temperature with rabbit antibodies against STAT5b 
diluted 1:100 in PBS containing 1% BSA.  After 4 washings for 5 min in PBS, 
the cells were incubated for 1 h at room temperature with a 1:200 dilution of 
Fluorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG (Pierce 
Biotechnology Inc.) in PBS.  After washing in PBS, the glass slides were 
mounted under a coverslip in a 50% glycerol/50% PBS solution.  The slides 
were analyzed by laser scanning Confocal microscopy, using a Zeiss LSM 510 
version 2.8 SP1 Confocal System. 
Results 
Effect of GH on the proliferative response of EBV transformed cell lines from 
normal subjects and γc negative X-SCID patients 
It has been reported that GH enhances EBV transformed cell lines proliferation 
in vitro, its effect being direct and not mediated by IGF-I (16).  Thus, to 
evaluate a biological role of γc in GHR signaling, we evaluated the response of 
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EBV transformed lymphocytes (BCLs) from γc negative X-SCID patients and 
normal controls to GH stimulation.  As shown in Fig. 1A, GH enhanced 
proliferation of BCLs of control subjects in a dose-dependent fashion.  
Significant enhancement of [3H]thymidine uptake was observed at a GH 
concentration of 50 ng/ml, and the maximal effect was achieved at 200 ng/ml.  
In contrast, γc negative BCLs didn’t respond at any GH concentration.  To rule 
out that the observed phenomena were due to different numbers of the receptor 
molecules on the cell membrane, GHR expression was evaluated by flow 
cytometry analysis on control’s and patient’s cells (Fig. 1B).  No difference was 
found in the mean fluorescence intensity (130.99 + 28.19 vs 139.88 + 33.49 in 
patients and controls, respectively; p = NS) and in the percentage of positively 
stained cells (99.6 vs 99.7% and 99.8 vs 99.9%, respectively).  
 
Pattern of protein tyrosine phosphorylation induced through GHR engagement 
in patients and controls cells 
We next investigated the overall signal transduction properties of patients and 
control BCLs following GHR ligation by analysing the number and the timing 
of the proteins phophorylated on tyrosine residues.  Fig. 2 illustrates a 
representative immunoblot with anti-phosphotyrosine antibodies of whole cell 
lysates from patient’s and control’s BCLs following stimulation with GH for 5, 
15 or 30 min.  In contrast to what observed in control cells, in patients GH 
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stimulation failed to induce phosphorylation of proteins approximately of 90 
kDa, presumably corresponding to STATs molecules involved in the signal 
transduction through GHR.  This pattern of protein tyrosine phophorylation was 
also observed in freshly isolated PBMC from a healthy subject and a patient 
stimulated with the same concentration and for the same time, thus confirming 
the observation on BCLs (data not shown).   
 
GHR signal transduction pattern 
The 3 main signaling modules by which signal transduction through GHR 
occurs involve Mitogen-activated protein kinases/ERK1 and 2, STAT and the 
Phosphatidylinositol-3 kinase-protein kinase B signaling (7).  
 To evaluate whether the γc was involved in the GHR signaling events, 
we next focused on STAT5 molecule. As shown in Fig. 3A, in control’s 
BCLs, tyrosine phosphorylation of STAT5 was evident, with a peak of 
activity observed between 5 and 15 min after GH stimulation.  By contrast, in 
patient’s BCLs no phosphorylation of STAT5 was detectable after 
stimulation.  In all cell lines examined, STAT5b and STAT5a protein 
expression was comparable in patients and controls.   
To define whether the blockage in GHR signaling was specific of STAT5 
or involved other molecules as well, we then studied ERKs phosphorylation 
(Fig. 3B).  No difference of ERK1 and 2 phosphorylation between patient’ and 
  
137 
137 
control’ BCLs was appreciable.  As shown, the expression of the molecules was 
comparable in control and patient cells  
 
STAT5 nuclear translocation after GHR triggering 
Recently it has been reported that tyrosine phosphorylation of STATs molecules 
was not sufficient for the activation of the protein (18, 19).  Since the activated 
STAT5 translocates into the nuclei, confocal microscopy was initially used to 
test the subcellular localization of STAT5b in control and patient γc negative 
cells under resting conditions and after stimulation with GH.   
Patients and controls BCLs were stimulated with GH for 30 min, fixed 
and incubated with antiserum against STAT5b.  As shown in Fig. 4, under basal 
conditions all cells displayed fluorescent staining of the cytoplasm indicating 
the presence of STAT5b in this compartment, and only a negligible staining of 
nucleus indicating absence of STAT5b in this compartment.  Stimulation with 
GH for the time indicated induced nuclear translocation of STAT5b in the 
control’s BCLs, as demonstrated by the marked increase in STAT5b 
immunoreactivity within the nucleus and not in γc negative BCLs.   
We next evaluated by immunoblot of nuclear and cytoplasmic extracts the 
amount of STAT5b translocation and compared it with the tyrosine 
phosphorylation of the molecule.  As shown in Fig. 5, in controls cells GH 
stimulation determined a rapid increase of nuclear STAT5b amount.  The 
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translocation occurred early being evident 5 min after GH stimulation.  
Moreover, it still persisted 30 min after the stimulation.  The translocation 
paralleled the amount of the tyrosine phosphorylated form of the protein into the 
nuclei.  This was inversely correlated with the amount of the cytoplasmic form 
of the molecule.  However, after 30 min the reconstitution of the cytoplasmic 
aliquot became evident.  In the patient cells no changes were observed 
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Discussion 
In the present study, we examined a potential role of the common cytokine 
receptor γ chain (γc) in GHR signaling using BCLs from healthy control 
subjects and γc negative X-SCID patients.   
At a functional level, GH enhanced proliferation of control BCLs in a 
dose dependent fashion.  By contrast, the functional response to GH of 
γc negative patients BCLs was severely impaired despite a comparable cellular 
expression of GHR molecules.    
The overall signal transduction properties of GHR in X-SCID patients and 
control BCLs following GH stimulation was also examined by analysing the 
pattern of protein tyrosine phosphorylation.  In contrast to what observed in 
control BCLs, in patients, GH stimulation failed to induce phosphorylation of 
proteins of 90 kDa identified as belonging to the STAT molecules family, 
involved in the signal transduction through GHR.  In particular, after GH 
stimulation no phosphorylation of STAT5 protein was observed in γc negative 
patients cell lines in contrast to the control cells, in which a prompt activation of 
STAT5 occurred.   
STAT-dependent pathways are generally believed to be utilized in 
cellular events such as cell proliferation, differentiation and apoptosis (20, 21), 
even though the overall role of the STAT molecules in GHR signal transduction 
has not been fully elucidated.  At least three different STAT family members 
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(STAT1, STAT3 and STAT5) are activated following GHR perturbation (22-
27), even though STAT5 seems to play a prominent role in receptor signaling.  
Rodent models of STAT knockouts (28) and the recent identification of a 
patient with a homozygous missense mutation of STAT5b gene indicate that 
STAT5b is essential for a normal postnatal linear growth (29).  Furthermore, the 
patient with STAT5b mutation also had clinical features of immune deficiency 
such as chronic diarrhea and severe infections, including interstitial 
pneumopathy.  Immunologic studies showed hypergammaglobulinemia and 
markedly decreased IL-2Rα chain expression in response to IL-2 stimulation, 
suggestive of a T-Cell activation defect.  Thus, a few features are similar to γc 
negative X-SCID patients.   
Although the activation of JAKs and STATs represents a prominent 
biochemical event during GH-dependent proliferation of lymphoid cell lines 
(30), other signaling pathways also contribute to a full GHR response.  GH has 
been shown to activate the phosphatidylinositol-3 kinase-protein kinase B 
signaling (31), mitogen-activated protein kinases and extracellular regulated 
kinases 1 and 2 (ERK1 and 2) (32-34).  In both STAT5 knockout mouse and in 
the patient with STAT5 mutation, these pathways are fully functional.  In 
keeping with this observation, also in our experimental model, no alteration was 
observed in ERK 1 and 2 expression and phosphorylation that occur following 
GHR triggering.  An increase in total STAT1 and STAT3 concentrations was 
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observed in STAT5 knockout rodent models and in the fibroblast cell line 
originated from STAT5 mutated patient (29, 35).  In our experimental condition, 
no other alteration of the GH-induced signaling through STAT pathways was 
observed (data not shown).  Taken together, these observations imply that GHR, 
as well as other receptors, is able to integrate different pathways which are 
individually differentially regulated.  In support of this, it has been recently 
shown that GHR signaling and the subsequent IGF-I transcription regulation are 
under different regulatory controls in hepatocytes, fibroblasts and myoblasts 
(36).  This could lead to hypothesize differential functions of an individual 
receptor exerted in different tissues.  A cell type-restricted STATs activation has 
been reported (37-39).  STAT5 is not activated following GH stimulation in 
human fibrosarcoma cells even though these cells express the STAT5 protein 
(39), thus implying that a selectivity in the involvement of specific STAT subset 
seems to be a general feature of GHR signal transduction. 
Overall, activation of STAT5b is considered a prominent event in GHR 
signaling and is crucial for the regulation of transcription of GH-responsive 
genes, including the gene encoding for IGF-I.  This process relies on an 
appropriate phosphorylation and nuclear translocation of the molecule (7, 40).  
Recently, it has been proposed that STATs tyrosine phosphorylation and nuclear 
translocation are two events that are regulated separately (19).  In particular, 
Giron-Michel J. and coworkers demonstrated in the hybrid receptor γc/GM-
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CSFRβ that γc/JAK3 complex controls the nuclear translocation of pSTAT5 
rather than STAT5 phosphorylation itself (41).  Hence to address the issue of 
defining the functional implication of γc mutation on STAT5b activation, in our 
study, the subcellular localization of STAT5b was investigated by analyzing 
cytokine-induced translocation of STAT5b from the cytoplasm to the nucleus 
with confocal microscopy.  Stimulation with GH induced nuclear translocation 
of STAT5b in the control cells, whereas no efficient nuclear translocation 
occurred in γc negative cells.  Furthermore, immunoblot of nuclear and 
cytoplasmic extracts showed in control cells a rapid increase of the nuclear 
fraction of the STAT5 molecule after GH stimulation, which paralleled the 
molecule phosphorylation, differently from what observed in patient cells. 
It is to note that none of the sequence motifs implicated in the STAT-receptor 
interaction is present in the GHR.  Therefore, STAT interaction with the GHR 
has to be mediated through adaptor molecules as SHC proteins (42, 43), JAKs-
STAT direct association or, alternatively, through additional adaptor subunits 
yet not identified (39).   
Our data suggest that the γc chain is a required signaling subunit of the 
GHR complex in B cell lines.  In particular, in this cell line, it is selectively 
required for STAT5 phosphorylation and nuclear translocation, and not for the 
activation of other molecules as ERKs.   
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Our study demonstrates the existence of a previously unappreciated 
relationship between individually well studied elements, such as GHR and γc, 
and signaling pathways.  Crosstalk between receptor signaling systems is now 
emerging as an important and exciting area of signaling research.  Whether the 
participation of γc to the GHR confers some additional properties to the receptor 
in hematopoietic cell differentiation and functioning remains to be elucidated.  
To note, in CD34+ progenitors, γc participates to hematopoietic cell 
differentiation by interacting with GM-CSFRβ.  This interaction does not occur 
in normal natural killer cells or non hematopoietic cells (41).  Hence, the 
complexity of receptor signaling relies not only on the possibility that individual 
receptors interact one with each other, but also on a differential array of distinct 
subunits that may represent a hallmark of that specific cell type.  
Our current study also leads to explain what our group previously 
reported on an atypical X-SCID phenotype and severe short stature associated 
with growth hormone hypo-responsiveness and abnormal GHR induced protein 
tyrosine phosphorylation (14), and indicates that growth failure in X-SCID is 
directly related to the genetic alteration.  
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Figure legends 
FIGURE 1.  In vitro effect of GH stimulation on proliferation of X-SCID 
patients’ and controls’ EBV cell lines. A, Lymphoblastoid cell lines (BCLs) 
were generated by Epstein-Barr virus immortalization of patients’ and controls’ 
PBMC using standard procedures (15) and cultured in the presence of various 
concentrations of GH for 4 days.  Cultures were pulsed with [3H]thymidine for 
the final 8 h and radioactive incorporation counted. Results are expressed as the 
increase of cpm from the background.  Vertical bars indicates 1 SD. B, The flow 
cytometry analysis indicating that the expression levels of GHR are comparable 
in controls and patients.   
 
FIGURE 2.  Pattern of protein tyrosine phosphorylation induced through GHR 
engagement.  BCLs from X-SCID patients and healthy subjects were starved of 
serum for 8-12 h and then stimulated with GH (500 ng/ml) at 37°C for the 
indicated time.  Stimulation was stopped with cold PBS and BCLs were 
resuspended in lysis buffer.  After SDS-PAGE and Western blot, membranes 
were incubated with anti-phosphotyrosine antibodies.  
 
FIGURE 3.  STAT5 and ERKs phosphorylation induced through GHR 
stimulation.  rGH stimulation failed to induce STAT5 tyrosine phosphorylation 
but not ERKs activation in γc negative BCLs.  BCLs from X-SCID patients and 
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healthy subjects were starved of serum for 8-12 h and then stimulated with GH 
(500 ng/ml) at 37°C for the indicated time.  After SDS-PAGE and Western blot, 
membranes were incubated with (A) anti-pSTAT5, anti-STAT5a or anti-
STAT5b or (B) anti-ERK (recognizing both ERK1 and ERK2) or anti-
phosphotyrosyl ERK antibodies.  
 
FIGURE 4.  STAT5b subcellular localization.  X-SCID patients and healthy 
subjects control cells were cultured in the absence or presence of 500 ng/ml rGH 
for 30 min at 37°C.  Unstimulated or stimulated cells were analyzed by 
Confocal microscopy for STAT5b (green) distribution in the cell, focusing 
particularly on whether this protein was present in the nuclei. 
 
FIGURE 5.  Nuclear fraction of the overall STAT5b amount and of the 
phosphorylated form of STAT5 in resting or rGH stimulated BCLs.  Patient and 
control BCLs were stimulated with rGH (500 ng/ml) or medium alone at 37°C 
for the indicated time.  Stimulation was stopped with cold PBS and nuclei were 
isolated as described in Materials and methods.  After SDS-PAGE of nuclear 
and cytoplasmic extracts and Western blot, membranes were incubated with 
anti-STAT5b or anti-pSTAT5 antibodies.   
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Methods 
Perforin  mutation analysis 
 
Genomic DNA was isolated from peripheral blood lymphocytes and the exons 2 
and 3 of the PRF1 coding region amplified using standard PCR conditions.  
PCR products were recovered from 1.5% agarose with a size marker, purified 
using QIAquick Gel extraction kit (QIAGEN, Hilden, Germany) and sequenced 
in an automatic ABI 377 DNA sequencer (Applied Biosystems, Foster City, 
CA, USA).  
 
Natural Killer function 
 
Infected target cells (K562) were pulsed for 1 h at 37 °C with Cr51(Amersham 
Pharmacia, Buckinghamshire, England) (30 Ci/106 cells) and washed three 
times with culture medium before the addition of effector cells.  Specific lysis 
was measured in a triplicate assay performed with 5x103 target cells mixed with 
different ratios of effector cells (E:T= 25:1 to 3.125:1) in a total volume of 200 
µl.  After a 5 h incubation at 37 °C, 100 µl culture supernatant were collected 
and the amount of Cr51 release was counted.  The percentage of specific lysis 
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was calculated as follows: 100 x (specific release-spontaneous release)/(total 
release-spontaneous release). 
Evaluation of Fas-induced cell death 
Fas-induced cell death was evaluated as previously reported on activated T-cell 
lines obtained by treating peripheral blood mononuclear cells (PBMC) with 
phytohemagglutinin (PHA) at days 0 (1 µg/mL) and 12 (0.1 µg/mL). Cells were 
then cultured in RPMI 1640 + 10% FCS + recombinant IL-2 (2 U/mL) (Biogen, 
Geneva, Switzerland).  Fas function was assessed 6 days after the second 
stimulation (day-18 T cells), by incubating with control medium or 1 µg/mL 
anti-Fas mAb (CH11, IgM isotype, UBI, Lake Placid, NY) in the presence of 1 
U/mL recombinant interleukin 2 (rIL-2) and 5% FCS to minimize spontaneous 
cell death.  Cell survival was evaluated after 18 hours by counting alive cells in 
each well by the trypan blue exclusion test.  Assays were performed in triplicate 
and analysed by a blind observer.  Cells from 2 normal donors were included in 
each experiment as a positive control.  Results were expressed as relative cell 
survival percentage, calculated as follows: (total live cell count in the assay 
wells/total live cell count in the untreated samples) x 100.  Spontaneous cell loss 
in the control well was always less than 10% of the seeded cells and similar in 
cultures from the patients and normal donors.  Cell death was evaluated both 
indirectly, by counting total surviving cells by the trypan blue exclusion test, or 
directly, by cytometric determination of the proportion displaying DNA 
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fragmentation after staining with propidium iodide or those stained by annexin 
to confirm Fas resistance. Fas function was defined defective when cell survival 
was higher than 78 %, which was the 95th percentile of the response displayed 
by normal controls. 
 
Molecular analysis of the Fas and caspase-8 genes 
Mutation analysis of the Fas (TNFRSF6) and caspase-8 genes were performed 
by DNA genomic sequencing. DNA was extracted from PBMC with standard 
methods. Eight fragments spanning the 5’UTR and the 9 exons of the Fas gene 
were amplified in 20 µl final volume containing 12 pmol of each primer, 50 ng 
of genomic DNA and 0,5 units of AmpliTaq (Applied Biosystems, Warrington, 
UK).  PCR conditions for caspase-8 gene amplification were as follows: sixteen 
fragments spanning the 10 exons and intron-exon boundaries were amplified in 
50 µl final volume containing 25 pmol of each primer, 100 ng of genomic DNA, 
0.2 mM dNTPs and 1.25 units of AmpliTaq Gold (Applied Biosystems) in the 
buffer provided by the manufacturer.  Amplification was performed in a Gene 
Amp PCR System 9700 (PE Applied Biosystems).  The PCR products were 
sequenced using a Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems) and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). 
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Cells and cell cultures 
Mononuclear cells (PBMC) were obtained from 4 X-SCID patients and normal 
donors heparinized peripheral blood by Ficoll-Hypaque (Biochrom) density 
gradient centrifugation.  Upon informed consent, lymphoblastoid cell lines 
(BCLs) were generated by Epstein-Barr virus immortalization of patients and 
controls PBMC using standard procedures (15).  In all cases, c mutations led 
to the absence of protein expression.  Cells were maintained in RPMI 1640 
(Biochrom) supplemented with 10% fetal bovine serum (Gibco), 2 mmol/L L-
glutamine (Gibco), and 50 µg/ml gentamycine (Gibco), and cultured at 37°C, 
5% CO2.   
 
Proliferative assay 
BCLs (1 X 105 cell/200 µl well) were cultured triplicate in 96-well U-bottomed 
microtiter plates (Falcon®, Becton Dickinson) with or without rGH at reported 
concentrations for 4 days.  The proliferative response was evaluated by 
thymidine uptake from cultured cells pulsed with 0.5 µCi [3H]thymidine 
(Amersham International) 8 h before harvesting . 
 
Flow cytometry 
The expression of GHR was detected using specific rabbit antibodies (Santa 
Cruz) by indirect immunofluorescence using a second-step incubation with a 
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FITC-conjugated donkey anti-rabbit antibodies (Pierce).  After washing in PBS, 
cells were incubated for 20 min with the specific antibodies and 30 min with 
secondary antibodies.  After staining, all samples were washed in PBS and 
acquired on the FACScan flow cytometer (Becton-Dickinson) using Lysis I 
software. 
 
Cell stimulation and protein extraction 
Prior to hormone treatment, the cells were made quiescent through incubation in 
RPMI 1640 minus serum for 8-12 h.  GH was used at 37°C at a concentration of 
500 ng/ml in RPMI 1640 for the reported time.  Incubations were terminated by 
washing cells with ice cold phosphate-buffer saline  (PBS; BioWhittaker) 
followed by solubilization in 100 µl of lysis solution containing 20 mM Tris 
(pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mmol EDTA, 1 mM 
phenylmethylsulfonylfluoride, 1 mM sodium orthovanadatum (Na3VO4), 5 
µg/ml leupeptin and 5 µg/ml aprotinin.  The cell lysates were stored at -80°C for 
Western blot analysis.  Nuclear extracts were prepared by the standard method 
and were subsequently mixed with sample buffer. 
 
Western blot 
Immunoblotting using phosphotyrosine monoclonal antibody was performed as 
previously reported.  Immunoblotting using specific antibody was performed 
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according to the vendors protocols.  In brief, protein samples separated by SDS-
PAGE were transferred onto Mixed Cellulose Esters membranes (Immobilon-
NC Mixed Cellulose Esters 0.45 µm; Millipore).  The membrane was incubated 
at room temperature for 1 h in blocking buffer consisting of 10% Bovin Serum 
Albumin (BSA) in wash buffer (10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% 
Tween 20).  The membrane was then washed three times in wash buffer and 
incubated 1 h at room temperature or overnight at 4°C with the specific 
antibody.  The membrane was then washed three times and an appropriate IgG 
horseradish peroxidase-coniugated secondary antibody was used for the second 
incubation.  After further washings, the membrane was developed with ECL 
developing reagents, and exposed to x-ray films according to the manufacturer’s 
instructions (Amersham Biosciences).   
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 Summary 
 
Primary immunodeficiency diseases (PIDs) represent a group of most 
heterogeneous syndromes characterized by development or functional defect of 
the Immune system.  More than 100 inherited conditions described 
immunodeficiencies exist.   Clinical presentation is highly variable, ranging 
from various patterns of microbial susceptibility to allergy, lymphoproliferation 
or autoimmune manifestation the most of these syndromes are monogenic and 
lead to defects in any aspect of the immune response.  Although several form of 
them occur in the first time of life there are many other disorders in which the 
clinical manifestation develop during adulthood.  Along with typical form of 
these syndromes there are several disease in which the clinical signs are less 
suggestive of immunodeficiency.  In these form it is very difficult make the 
diagnosis. In the course of this PhD program we try to better clarify for some of 
these complex phenotypes the correlation between genotype and phenotype, 
identify the biochemical biomarkers that make possible the diagnosis and 
eventually clarify the pathogenesis mechanism  of these syndromes.   
 
  
169 
169 
Acknowledgement 
I would you like to thank all the people who helped and supported me 
during my studies leading to the realization of this work.  In particular, I would 
you like to thank my supervisor Prof. Claudio Pignata, for the opportunity he 
gave me to work in his group.  He has been a great supporter because he has 
supported and encouraged me during all these years.  Moreover, he followed me 
in the PhD program and in my research supporting my decision and influencing 
my work with stimulating advice.   
Moreover I also like to acknowledge Marsilio Adriani for his help and 
support in the laboratory.  He is not only a colleague but is also a dear friend. 
  
170 
170 
Curriculum Vitae 
Busiello Rosanna was born on June 24, 1977 in Portici (Naples), Italy. Her 
educational and professional position are listed below. 
Educational/Training 
• High School degree 
 
• 2001 “Federico II” University of Naples Degree in Biology, summa cum 
lode 
• 2002 post-graduate fellow at the Department of Pediatrics of “Federico 
II” University of Naples 
• 2002 PhD student in “Sviluppo, Accrescimento e Riproduzione 
dell’uomo” at the “Federico II” University, Naples, Italy 
SKILLS: 
 
- Computer literate, knowledge of MS Windows, MacOS  systems 
- Good knowledge of scientific softwares as:  Oligo 4, Gencokit, DNA 
strider, Cyrillic 3, NIH image (Mac and PC version), Lysis 2.   
- Expertise in utilizing common online databases of proteins 
(Swissprot/TrEMBL, PIR, UniProt, Prosite, ect), nucleotide sequences 
(GeneBank.EMBL, DDBJ), mouse models (MGI, MPD, GXD, etc).  
- knowledge of written and spoken English 
  
171 
171 
TECHNOLOGYCAL SKILS 
 
Direct experience in the following fields:   
- Cell cultures 
- DNA and RNA extractions  
- PCR 
- Direct Sequencing 
- SSCP 
- Western Blotting 
 
AWARDS 
 
2003- Award from “Federation of Clinical Immunology Societies”for the 
following abstract:    "Atypical Features of Familial Haemofagocytic 
Llymphoistiocitosis." (Paris May, 2003) 
 
2003-Award “1° Premio Città di Caserta” with the work entitled: “Atypical 
Features of Familial Haemofagocytic Llymphoistiocitosis”(Aversa 
November, 2003) 
 
 
 
  
172 
172 
 
 
  
173 
173 
List of papers 
 
I. Salerno M, Busiello R, Esposito V, Cosentini E, Adriani M, Selleri 
C,  Rotoli B, Pignata C. Allogeneic bone marrow transplantation 
restores IGF-I production and linear growth in a gamma-SCID 
patient with abnormal growth hormone receptor signaling. Bone 
Marrow Transplant. 33:773-5, 2004;. 
 
II. Busiello R., Greco G., Pignata C.  Novel Immunodeficiencies: 
clustering of distinct autoimmune disorders associated to 
monogenic alteration. It  J Ped. 30: 95-102, 2004 
 
 
III. Adriani M, Martinez-Mir A, Fusco F, Busiello R, Frank J, Telese S, 
Matrecano E, Ursini MV, Christiano AM, Pignata C. Ancestral 
founder mutation of the nude (FOXN1) gene in congenital severe 
combined immunodeficiency associated with alopecia in southern 
Italy population. Ann Hum Genet. 68: 265-8, 2004;. 
 
IV. Busiello R, Adriani M, Locatelli F, Galgani M, Fimiani G, 
Clementi R, Ursini MV, Racioppi L, Pignata C. Atypical features 
of familial hemophagocytic lymphohistiocytosis. Blood 103: 4610-
2, 2004.  
 
 
V. Busiello R., Galgani M., De Fusco C., Poggi V., Adriani M., 
Racioppi L., Pignata C. A91V is a polymorphism in the perforin 
gene not causative of an FHLH phenotype. Blood 104: 1909-1910, 
2004 
 
VI. Busiello R, Figiani G., Miano M.G., Aricò M., Santoro A., Ursini 
M. V. and Pignata C. A91V perforin variation in healthy subjects 
and FHLH patients. (Submitted to International Journal of 
Immunogenetics) 
 
VII. Adriani M., Auricchio L., Frank J., Busiello R.,, Christiano A.M., 
Pignata C. Nail dystrophy associated with heterozygous mutation 
of the Nude/SCID FOXN1 (WHN) gene. Arch Dermatol 141: 647-
648, 2005  
 
  
174 
174 
 
VIII. Adriani M., Garbi C., Amodio G., Busiello R., Matrecano E., 
Cosentini E., Candotti F., Pignata C.  Functional Interaction of 
Common Gamma Chain and Growth Hormone Receptor Signaling 
Apparatus.  Journal of Immunology (submitted) 
 
IX. Ferri P., Lombardi F., Franzese A., Busiello R., Chiocchetti A., 
Ramenghi U., Dianzani U., Pignata C. Pattern of phenotypic 
expression and familial occurrence of clustering of autoimmune 
disorders in childhood. Haematologica (Submitted) 
 
 
 
 
 
 
